Ablynx’s strategy is to use the Company’s unique Nanobody technology to develop therapeutics in areas of high unmet medical need where Nanobodies offer a clear promotable advantage over existing products and technologies.

The Company employs a hybrid business model where it invests directly in its own development programmes as well as collaborating with pharmaceutical partners at all stages of discovery and development. Where there are appropriate opportunities, Ablynx will retain some or all rights to commercialise its products.

Ablynx’s ambition is to develop differentiated and innovative medicines which have the potential to make a real difference to society, as well as creating sustainable value for all its stakeholders.